Literature DB >> 10630554

Assessing the structure and process for providing pharmaceutical care in Veterans Affairs medical centers.

S J Billups1, G Okano, D Malone, B L Carter, R Valuck, D J Barnette, C D Sintek.   

Abstract

The structure and process used in providing pharmaceutical care to ambulatory care patients at nine Veterans Affairs medical centers (VAMCs) were studied. Institutions participating in the IMPROVE (Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers) study were selected. To assess the level of pharmaceutical care services provided to ambulatory care patients, 10 critical domains were identified. Six instruments with questions related to each domain were then designed, including a clinical pharmacist survey and an outpatient pharmacist survey. Each center was assessed through three surveys and an onsite visit. The investigators used both direct observation and a consensus approach to score the level of ambulatory care pharmaceutical services provided. The clinics in which IMPROVE study patients would be seen were run by pharmacists (33%), physicians (44%), and multidisciplinary teams (22%). Of the 51 clinical pharmacists surveyed, 23 (45%) had prescribing authority via protocols, 14 (28%) had unrestricted prescribing privileges, and 14 did not have prescribing authority. The sites varied greatly in referral patterns, methods of identifying patients, and whether patient visits were scheduled or on a walk-in basis. There was a strong correlation between observed activities by clinical pharmacists and their self-reports and between observed activities by outpatient pharmacists and their self-reports. Activities reported by clinical pharmacists were moderately but not significantly correlated with consensus scores, and activities reported by outpatient pharmacists were poorly correlated with consensus scores. The structure and process for providing pharmaceutical care to ambulatory care patients at VAMCs were evaluated with surveys, direct observation, and a consensus-based scoring system.

Entities:  

Mesh:

Year:  2000        PMID: 10630554     DOI: 10.1093/ajhp/57.1.29

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  10 in total

1.  A cluster-randomized effectiveness trial of a physician-pharmacist collaborative model to improve blood pressure control.

Authors:  Barry L Carter; William Clarke; Gail Ardery; Cynthia A Weber; Paul A James; Mark Vander Weg; Elizabeth A Chrischilles; Thomas Vaughn; Brent M Egan
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2010-07

2.  Physician-pharmacist collaborative management of asthma in primary care.

Authors:  Tyler H Gums; Barry L Carter; Gary Milavetz; Lucinda Buys; Kurt Rosenkrans; Liz Uribe; Christopher Coffey; Eric J MacLaughlin; Rodney B Young; Adrienne Z Ables; Nima Patel-Shori; Angela Wisniewski
Journal:  Pharmacotherapy       Date:  2014-08-20       Impact factor: 4.705

3.  Physician-Pharmacist Collaborative Management: Narrowing the Socioeconomic Blood Pressure Gap.

Authors:  Maxwell D Anderegg; Tyler H Gums; Liz Uribe; Christopher S Coffey; Paul A James; Barry L Carter
Journal:  Hypertension       Date:  2016-09-06       Impact factor: 10.190

Review 4.  Cluster randomized trials for pharmacy practice research.

Authors:  Tyler Gums; Barry Carter; Eric Foster
Journal:  Int J Clin Pharm       Date:  2015-12-29

5.  Pharmacist intervention for blood pressure control: medication intensification and adherence.

Authors:  Tyler H Gums; Liz Uribe; Mark W Vander Weg; Paul James; Christopher Coffey; Barry L Carter
Journal:  J Am Soc Hypertens       Date:  2015-05-15

6.  Cluster-randomized trial of a physician/pharmacist collaborative model to improve blood pressure control.

Authors:  Barry L Carter; Christopher S Coffey; Gail Ardery; Liz Uribe; Dixie Ecklund; Paul James; Brent Egan; Mark Vander Weg; Elizabeth Chrischilles; Thomas Vaughn
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2015-03-24

7.  Using theory to predict implementation of a physician-pharmacist collaborative intervention within a practice-based research network.

Authors:  David E Demik; Mark W Vander Weg; Emily S Lundt; Christopher S Coffey; Gail Ardery; Barry L Carter
Journal:  Res Social Adm Pharm       Date:  2013-03-16

8.  Similar blood pressure values across racial and economic groups: baseline data from a group randomized clinical trial.

Authors:  Barry L Carter; Christopher S Coffey; Liz Uribe; Paul A James; Brent M Egan; Gail Ardery; Elizabeth A Chrischilles; Dixie Ecklund; Mark Vander Weg; Thomas Vaughn
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-04-01       Impact factor: 3.738

9.  Pharmacist Intervention for Blood Pressure Control in Patients with Diabetes and/or Chronic Kidney Disease.

Authors:  Maxwell D Anderegg; Tyler H Gums; Liz Uribe; Eric J MacLaughlin; James Hoehns; Oralia V Bazaldua; Timothy J Ives; David L Hahn; Christopher S Coffey; Barry L Carter
Journal:  Pharmacotherapy       Date:  2018-02-23       Impact factor: 4.705

10.  Cost-Effectiveness of a Physician-Pharmacist Collaboration Intervention to Improve Blood Pressure Control.

Authors:  Linnea A Polgreen; Jayoung Han; Barry L Carter; Gail P Ardery; Christopher S Coffey; Elizabeth A Chrischilles; Paul A James
Journal:  Hypertension       Date:  2015-11-02       Impact factor: 10.190

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.